Functional imaging of non-motor signs in Parkinson's disease

Journal of the Neurological Sciences

Volumn 315, Issue 1-2, 2012, Pages 9-14

  Ballanger, Bénédicte ^a   Poisson, Alice ^a,b,c   Broussolle, Emmanuel ^a,b,c   Thobois, Stéphane ^a,b,c  

^a INSTITUT DES SCIENCES COGNITIVES   (France)

^b HÔPITAL NEUROLOGIQUE   (France)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

MRI; Non motor; Parkinson; PET; SPECT

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 6 FLUORODOPA F 18; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; AMYLOID BETA PROTEIN; LEVODOPA; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE C 11; NOMIFENSINE C 11; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; APATHY; BEHAVIOR DISORDER; BRAIN BLOOD FLOW; BRAIN DEPTH STIMULATION; BRAIN DYSFUNCTION; BRAIN METABOLISM; BRAIN PERFUSION; COGNITION; COGNITIVE DEFECT; DEMENTIA; DEPRESSION; DISEASE ASSOCIATION; DOPAMINE DYSREGULATION SYNDROME; DYSAUTONOMIA; FATIGUE; FUNCTIONAL NEUROIMAGING; HUMAN; HYPOSMIA; IMPULSE CONTROL DISORDER; MENTAL DISEASE; NEUROTRANSMISSION; NONMOTOR SIGN; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PARKINSON DISEASE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DISORDER; SUBTHALAMIC NUCLEUS; SYMPTOM; VISUAL HALLUCINATION;

ANIMALS; DIAGNOSTIC IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84857998902     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2011.11.008     Document Type: Review

References (82)

1. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464-74.
2. Funkiewiez A, Ardouin C, Krack P, Fraix V, VanBlercom N, Xie J, et al. Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease. Mov Disord 2003;18:524-30. (Pubitemid 36656536)
3. Maricle RA, Nutt JG, Valentine RJ, Carter JH. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study. Neurology 1995;45:1757-60.
4. Ballanger B, Jahanshahi M, Broussolle E, Thobois S. PET functional imaging of deep brain stimulation in movement disorders and psychiatry. J Cereb Blood Flow Metab 2009;29(11):1743-54.
5. Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 2008;15(70(16 Pt 2)):1470-7.
6. Yong SW, Yoon JK, An YS, Lee PH. A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies. Eur J Neurol 2007;14(12):1357-62. (Pubitemid 350135301)
7. Kadir A, Nordberg A. Target-specific PET probes for neurodegenerative disorders related to dementia. J Nucl Med 2010;51(9):1418-30.
8. Gilman S, Koeppe RA, Little R, An H, Junck L, Giordani B, et al. Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing. Exp Neurol 2005;191(Suppl. 1):S95-S103. (Pubitemid 40081108)
9. Kanda T, Ishii K, Uemura T, Miyamoto N, Yoshikawa T, Kono AK, et al. Comparison of greymatter andmetabolic reductions in frontotemporal dementia using FDG-PET and voxel-based morphometric MR studies. Eur J Nucl Med Mol Imaging 2008;35(12):2227-34.
10. Broussolle E, Dentresangle C, Landais P, Garcia-Larrea L, Pollak P, Croisile B, et al. The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease. J Neurol Sci 1999;166(2):141-51. (Pubitemid 29339086)
11. Holthoff-Detto VA, Kessler J, Herholz K, Bönner H, Pietrzyk U, Würker M, et al. Functional effects of striatal dysfunction in Parkinson disease. Arch Neurol 1997;54(2):145-50. (Pubitemid 27078721)
12. Ito K, Nagano-Saito A, Kato T, Arahata Y, Nakamura A, Kawasumi Y, et al. Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F] fluoro-L-dopa PET study. Brain 2002;125(Pt. 6):1358-65. (Pubitemid 34587144)
13. O'Brien JT, McKeith IG, Walker Z, TatschK, Booij J, Darcourt J, et al. Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementiawith Lewy bodies. Br J Psychiatry 2009;194(1):34-9.
14. Rinne JO, Portin R, Ruottinen H, Nurmi E, Bergman J, Haaparanta M, et al. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F] fluorodopa positron emission tomographic study. Arch Neurol 2000;57(4):470-5. (Pubitemid 30212118)
15. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Constantine GM, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 2006;253(2):242-7. (Pubitemid 43255898)
16. Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, Burghaus L, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005;65(11):1716-22.
17. Klein JC, Eggers C, Kalbe E, Weisenbach S, Hohmann C, Vollmar S, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010;74(11):885-92.
18. Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003;60(12):1745-8. (Pubitemid 37521630)
19. Shinotoh H, Namba H, Fukushi K, Nagatsuka S, Tanaka N, Aotsuka A, et al. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a positron emission tomography study. Ann Neurol 2000;48(2):194-200. (Pubitemid 30617038)
20. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008;131(Pt. 6):1630-45. (Pubitemid 351806448)
21. Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008;79(12):1331-8.
22. Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008;71(12):903-10.
23. Maetzler W, Reimold M, Liepelt I, Solbach C, Leyhe T, Schweitzer K, et al. [11C]PIB binding in Parkinson's disease dementia. Neuroimage 2008;39(3):1027-33.
24. Foster ER, Campbell MC, Burack MA, Hartlein J, Flores HP, Cairns NJ, et al. Amyloid imaging of Lewy body-associated disorders. Mov Disord 2010;25(15):2516-23.
25. Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 2005;58(5):773-6. (Pubitemid 41552553)
26. Kempster PA, O'Sullivan SS, Holton JL, Revesz T, Lees AJ. Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain 2010 Jun;133(Pt. 6):1755-62.
27. Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM. Dopaminergic-modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain 2002;125(Pt. 3):584-94. (Pubitemid 34194413)
28. Mattay VS, Tessitore A, Callicott JH, Bertolino A, Goldberg TE, Chase TN, et al. Dopaminergic modulation of cortical function in patients with Parkinson's disease. Ann Neurol 2002;51(2):156-64. (Pubitemid 34111437)
29. Farid K, Sibon I, Guehl D, Cuny E, Burbaud P, Allard M. Brain dopaminergic modulation associated with executive function in Parkinson's disease. Mov Disord 2009;24(13):1962-9.
30. Mentis MJ, Dhawan V, Nakamura T, Ghilardi MF, Feigin A, Edwards C, et al. Enhancement of brain activation during trial-and-error sequence learning in early PD. Neurology 2003;60(4):612-9. (Pubitemid 36246078)
31. Nakamura T, Ghilardi MF, Mentis M, Dhawan V, Fukuda M, Hacking A, et al. Functional networks inmotor sequence learning: abnormal topographies in Parkinson's disease. Hum Brain Mapp 2001;12(1):42-60. (Pubitemid 32048356)
32. Lewis SJ, Dove A, Robbins TW, Barker RA, Owen AM. Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci 2003;23(15):6351-6. (Pubitemid 36875637)
33. Sawamoto N, Piccini P, Hotton G, Pavese N, Thielemans K, Brooks DJ. Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. Brain 2008;131(Pt. 5):1294-302.
34. Oishi N, Udaka F, Kameyama M, Sawamoto N, Hashikawa K, Fukuyama H. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology Dec. 13 2005;65(11):1708-15.
35. Stebbins GT, Goetz CG, Carrillo MC, Bangen KJ, Turner DA, Glover GH, et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology 2004;63(8):1409-16. (Pubitemid 39426273)
36. Meppelink AM, de Jong BM, Renken R, Leenders KL, Cornelissen FW, van Laar T. Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations. Brain 2009;132(Pt. 11):2980-93.
37. Ramírez-Ruiz B, Martí MJ, Tolosa E, Falcón C, Bargalló N, Valldeoriola F, et al. Brain response to complex visual stimuli in Parkinson's patients with hallucinations: a functional magnetic resonance imaging study. Mov Disord 2008;23(16):2335-43.
38. Ballanger B, Strafella AP, van Eimeren T, Zurowski M, Rusjan PM, Houle S, et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 2010;67(4):416-21.
39. Aarsland D, Bronnick K, Alves G, Tysnes OB, Pedersen KF, Ehrt U, et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. J Neurol Neurosurg Psychiatry 2009;80:928-30.
40. Thobois S, Ardouin C, Schmitt E, Lhommée E, Klinger H, Xie J, et al. Behavioral disorders in Parkinson's disease: from pathophysiology to the mastery of dopaminergic treatment. Rev Neurol 2010;166(10):816-21.
41. Thobois S, Ardouin C, Lhommée E, Klinger H, Lagrange C, Xie J, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors, and underlying mesolimbic denervation. Brain 2010;133:1111-27.
42. Koerts J, Leenders KL, Koning M, Portman AT, van Beilen M. Striatal dopaminergic activity (FDOPA-PET) associated with cognitive items of a depression scale (MADRS) in Parkinson's disease. Eur J Neurosci 2007;25(10):3132-6. (Pubitemid 46888822)
43. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005;128(Pt. 6):1314-22. (Pubitemid 40826185)
44. Weintraub D, Newberg AB, Cary MS, Siderowf AD, Moberg PJ, Kleiner-Fisman G, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. J Nucl Med 2005;46(2):227-32. (Pubitemid 43073428)
45. Boileau I, Warsh JJ, Guttman M, Saint-Cyr JA, McCluskey T, Rusjan P, et al. Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB. Mov Disord 2008;23(12):1776-80.
46. Politis M, Wu K, Loane C, Turkheimer FE, Molloy S, Brooks DJ, et al. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology 2010;75(21):1920-7.
47. Ballanger B, Klinger H, Eche J, Lerond J, Vallet AE, Le Bars D, et al. Role of serotonergic 1A receptors dysfunction in depression associated with Parkinson's disease. Mov Disord Oct. 12 2011, doi:10.1002/mds.23895 [Epub ahead of print].
48. Fox SH, Chuang R, Brotchie JM. Serotonin and Parkinson's disease: On movement, mood, and madness. Mov Disord Jul. 15 2009;24(9):1255-66.
49. Drevets WC, Frank E, Price JC, Kupfer DJ, Holt D, Greer PJ, et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry 1999;46(10):1375-87.
50. Savitz J, Lucki I, Drevets WC. 5-HT(1A) receptor function in major depressive disorder. Prog Neurobiol 2009;88(1):17-31.
51. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010;67(5):589-95.
52. Ardouin C, Chéreau I, Llorca PM, Lhommée E, Durif F, Pollak P, et al. Assessment of hyper- and hypo-dopaminergic behaviours in Parkinson's disease. Rev Neurol (Paris) 2009;165:845-56.
53. Evans AH, Pavese N, Lawrence AD, Tai YF, Appel S, Doder M, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006;59(5):852-8. (Pubitemid 43673163)
54. Steeves TD, Miyasaki J, Zurowski M, Lang AE, Pellecchia G, Van Eimeren T, et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 2009;132(Pt. 5):1376-85.
55. O'Sullivan SS, Wu K, Politis M, Lawrence AD, Evans AH, Bose SK, et al. Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain 2011;134(Pt. 4):969-78.
56. Voon V, Gao J, Brezing C, Symmonds M, Ekanayake V, Fernandez H, et al. Dopamine agonists and risk: impulse control disorders in Parkinson's disease. Brain 2011;134(Pt. 5): 1438-46.
57. van Eimeren T, Pellecchia G, Cilia R, Ballanger B, Steeves TD, Houle S, et al. Druginduced deactivation of inhibitory networks predicts pathological gambling in PD. Neurology 2010;75(19):1711-6.
58. Cilia R, Siri C, Marotta G, Isaias IU, De Gaspari D, Canesi M, et al. Functional abnormalities underlying pathological gambling in Parkinson disease. Arch Neurol 2008;65(12):1604-11.
59. Pedersen KF, Alves G, Brønnick K, Aarsland D, Tysnes OB, Larsen JP. Apathy in drug-naïve patients with incident Parkinson's disease: the Norwegian Park West study. J Neurol 2010;257(2):217-23.
60. Czernecki V, Schupbach M, Yaici S, Levy R, Bardinet E, Yelnik J, et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord 2008;23:964-9.
61. Drapier D, Drapier S, Sauleau P, Haegelen C, Raoul S, Biseul I, et al. Does subthalamic nucleus stimulation induce apathy in Parkinson's disease? J Neurol 2006;253:1083-91. (Pubitemid 44441136)
62. Le Jeune F, Drapier D, Bourguignon A, Péron J, Mesbah H, Drapier S, et al. Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study. Neurology 2009;73(21):1746-51.
63. Migneco O, Benoit M, Koulibaly PM, Dygai I, Bertogliati C, Desvignes P, et al. Perfusion brain SPECT and statistical parametric mapping analysis indicate that apathy is a cingulate syndrome: a study in Alzheimer's disease and nondemented patients. Neuroimage 2001;13(5):896-902. (Pubitemid 32848334)
64. Holthoff VA, Beuthien-Baumann B, Kalbe E, Lüdecke S, Lenz O, Zündorf G, et al. Regional cerebral metabolism in early Alzheimer's disease with clinically significant apathy or depression. Biol Psychiatry 2005;57(4):412-21. (Pubitemid 40215772)
65. Karlsen K, Larsen JP, Tandberg E, Jørgensen K. Fatigue in patients with Parkinson's disease. Mov Disord 1999;14(2):237-41. (Pubitemid 30011839)
66. Pavese N, Metta V, Bose SK, Chaudhuri KR, Brooks DJ. Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. Brain 2010;133(11):3434-43.
67. Happe S, Baier PC, Helmschmied K, Meller J, Tatsch K, Paulus W. Association of daytime sleepiness with nigrostriatal dopaminergic degeneration in early Parkinson's disease. J Neurol 2007;254(8):1037-43. (Pubitemid 47353416)
68. Hilker R, Razai N, Ghaemi M, Weisenbach S, Rudolf J, Szelies B, et al. [18F]fluorodopa uptake in the upper brainstemmeasured with positron emission tomography correlates with decreased REM sleep duration in early Parkinson's disease. Clin Neurol Neurosurg 2003;105(4):262-9. (Pubitemid 37040787)
69. Braune S. The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clin Auton Res 2001;11(6):351-5. (Pubitemid 34461714)
70. Oka H, Yoshioka M, Morita M, Onouchi K, Suzuki M, Ito Y, et al. Reduced cardiac 123I-MIBG uptake reflects cardiac sympathetic dysfunction in Lewy body disease. Neurology 2007;69(14):1460-5.
71. Rascol O, Schelosky L. 123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders. Mov Disord 2009;24(Suppl. 2):S732-41.
72. Marini C, Bandettini di Poggio M, Pomposelli E, Marchese R, Nobili F, Morbelli SD, et al. Whole body and cardiac metaiodobenzylguanidine kinetics in Parkinson disease andmultiple systematrophy: implications for the diagnostic role of imaging. Clin Nucl Med 2010;35(5):311-6.
73. Nagayama H, Ueda M, Yamazaki M, Nishiyama Y, Hamamoto M, Katayama Y. Abnormal cardiac [(123)I]-meta-iodobenzylguanidine uptake in multiple system atrophy. Mov Disord 2010;25(11):1744-7.
74. Berendse HW, Booij J, Francot CM, Bergmans PL, Hijman R, Stoof JC, et al. Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann Neurol 2001;50(1):34-41. (Pubitemid 32591460)
75. Bohnen NI, Gedela S, Herath P, Constantine GM, Moore RY. Selective hyposmia in Parkinson disease: association with hippocampal dopamine activity. Neurosci Lett 2008;447(1):12-6.
76. Siderowf A, Newberg A, Chou KL, Lloyd M, Colcher A, Hurtig HI, et al. [99mTc]TRODAT 1 SPECT imaging correlates with odor identification in early Parkinson disease. Neurology 2005;64(10):1716-20. (Pubitemid 40695804)
77. Ponsen MM, Stoffers D, Wolters ECh, Booij J, Berendse HW. Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's disease. J Neurol Neurosurg Psychiatry 2010;81(4):396-9.
78. Bohnen NI, Müller ML, Kotagal V, Koeppe RA, Kilbourn MA, Albin RL, et al. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease. Brain 2010;133(Pt. 6):1747-54.
79. Serby M, Larson P, Kalkstein D. The nature and course of olfactory deficits in Alzheimer's disease. Am J Psychiatry 1991;148(3):357-60.
80. Chou KL, Bohnen NI. Performance on an Alzheimer-selective odor identification test in patients with Parkinson's disease and its relationship with cerebral dopamine transporter activity. Parkinsonism Relat Disord 2009;15(9):640-3.
81. Brefel-Courbon C, Payoux P, Thalamas C, Ory F, Quelven I, Chollet F, et al. Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord 2005;20(12):1557-63.
82. Dellapina E, Gerdelat-Mas A, Ory-Magne F, Pourcel L, Galitzky M, Calvas F, et al. Apomorphine effect on pain threshold in Parkinson's disease: A clinical and positron emission tomography study. Mov Disord 2011;26(1):153-7.